Anacor to Present at Cowen and Company Health Care Conference.PALO ALTO, Calif. -- Anacor Pharmaceuticals announced today that David Perry, Chief Executive Officer, will provide a company overview at the Cowen and Company 29th Annual Health Care Conference at 2:00 p.m. ET on Monday, March 16, 2009 in Boston. About Anacor Pharmaceuticals Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron boron (bōr`ŏn) [New Gr. from borax], chemical element; symbol B; at. no. 5; at. wt. 10.81; m.p. about 2,300°C;; sublimation point about 2,550°C;; sp. gr. 2.3 at 25°C;; valence +3. chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antiviral antiviral /an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts. an·ti·vi·ral adj. and antibacterial therapeutics under a research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail toenail /toe·nail/ (to´nal) the nail on any of the digits of the foot. ingrown toenail see under nail. toe·nail n. onychomycosis, which is a fungal infection fungal infection, infection caused by a fungus (see Fungi), some affecting animals, others plants. Fungal Infections of Human and Animals of the nail and nail bed nail bed n. The formative layer of cells at the base of the fingernail or toenail; the matrix. Also called keratogenous membrane, matrix unguis. Nail bed The layer of tissue underneath the nail. . AN2690 is licensed to Schering-Plough Corporation under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. For more information visit www.anacor.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion